Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MMAF

Financiado

Participar

Novel multimodal approach to atrial fibrillation risk assessment and identificat...

Novel multimodal approach to atrial fibrillation risk assessment and identification of targets for prevention by interdisciplinary exploitation of omics advanced electrocardiography and imaging There is a growing need for novel risk schemes in atrial fibrillation (AF) to permit prevention, contribute to a better understanding of the pathophysiology, and discover targets for individualized treatment. Primary prevention ef... ver más

30/06/2021

UKE

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100% 100%

2 Participantes

UKE

2.00M€ | Lider

CONSTRUCCIONES TECNICAS DE R...

316.89K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Últimas noticias

04-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1 concesiones

04-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 50 concesiones

04-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 5 concesiones

Duración del proyecto: 68 meses Fecha Inicio: 2015-10-15
Fecha Fin: 2021-06-30

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto There is a growing need for novel risk schemes in atrial fibrillation (AF) to permit prevention, contribute to a better understanding of the pathophysiology, and discover targets for individualized treatment. Primary prevention efforts are scant despite the imminent AF epidemic. In international cohorts I have developed and validated the first risk prediction algorithm. However, it explains only 60% of the attributable risk and efforts at improving discrimination are urgently required. Therefore, my overall goal is to develop an enhanced risk prediction algorithm based on cutting-edge technology. The specific focus will be on parameters representative of early stages of the disease process and intermediate phenotypes such as atrial electrical and structural remodelling, chronic subclinical inflammation, oxidative stress, and autonomous tone in manifest and incident AF. Subclinical, potentially reversible changes are ideally suited to provide independent information complementary to known risk markers. My ambitious concept is to choose a multimodal approach in an interdisciplinary team to systematically assess: 1) Blood and tissue omics (genomics, expression, proteomics, metabolomics), 2) Advanced electrocardiography, 3) Imaging (echocardiography, cardiac MRI), and 4) Gender applying innovative tools and analyses strategies aimed at a systems biology integration of the accumulated information. I have collected comprehensive biological and epidemiologic information on distinct AF phenotypes in unique prospective population (N>60,000) and clinical cohorts (N>1,000). We are not aware of other groups with access to such a well-established prospective AF biobank. Informed by omics, electrocardiography and imaging we will provide pathophysiological insights into the disease process, highlight targets for intervention, and develop a contemporary risk scheme. Our results will lay the ground for rapid translation into clinical practice with significant public health impact.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores